SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
SocialPicks Community
Epinex Diagnostics: A New Paradigm for Diabetic Testing
ABT
|
|
|
+2.31%
in
9 days
Epinex Diagnostics Inc. (click on preceding link for the Company's News Room page) is a private company that is dedicated to the development of innovative point-of-care technologies using rapid diagnostic tests. Epinex has developed a proprietary platform for rapid tests that apply existing immunoassay strips and biosensors to create unique quantitative diagnostic tests. Advantages of the Epinex Quantitative Immunoassay System for Point-of-Care Testing include the following: 1.) Rapid: Results within minutes. <> 2.) Quantitative: Yields a<><><><><><><>< /><><>< /><><><><><><><>< /><>< /><><><><><><><><><>...
|
FDA Calendar Updates: ABT, AFFY, AZN, LLY, MELA, PFE, VPHM
ABT
|
|
|
+18.76%
in
168 days
(closed on 11/19/09)
<> Below is a summary of updates to the <font> BioMedReports.com FDA Calendar </font> , which includes a database of about 200 entries. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following additional categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pen...
|
FDA and Clinical Trial Calendar Updates
ABT
|
|
|
-1.95%
in
71 days
(closed on 06/04/09)
FDA and Clinical Trial Calendar Updates <> The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA deadline dates. The entries are updated on a daily basis as new information becomes available with a total of 106 entries through 3/25/09. The FDA Calendar includes the fo...
|
New Index of Highly Defensive Market Cap Leaders
ABT
|
|
|
-16.34%
in
28 days
(closed on 03/25/09)
The ETF Innovators Highly Defensive Index contains 40 market cap leading companies which are based in either North America or Europe from the defensive industry groups (A-K) specified below. www.BioMedReports.com - Mike Havrilla (A) Mass Merchant Discount Retailer (1): Wal-Mart (WMT) <> <> (B) Consumer Staples (12): Coca-Cola (KO), Colgate-Palmolive (CL), Diageo (DEO), General Mills (GIS), Danone (GDNNY), Kraft Foods (KFT), Nestle (NSRGY), PepsiCo (PEP), Philip Morris International (PM), Procter & Gamble (PG), Reckitt Benckiser (RBGPF), Unilever (UN) <><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><>< />...
|
A More Focused Highly Defensive Index
ABT
|
|
|
+6.68%
in
83 days
(closed on 02/25/09)
<> 
The accompanying table [click to enlarge] includes an updated version of the ETF Innovators [ETFI] ETFI Highly Defensive PerformIdex of 36 companies based in the U.S., Canada, and Europe with market caps over $10B, which are the leaders by market cap in their defensive industry groups. This update includes a 10% reduction in the number of companies with an equal distribution of 12 each from consumer staples and healthcare, with the remaining 12 companies chosen from a variety of defensive industry groups.
(A) Mass Merch...
|
From the Blogosphere
Boston Scientific’s New Product – Analyst Blog
|
|
|
Boston Scientific Corp. (BSX) recently received 510(k) clearance from the U.S. Food and Drug Administration (FDA) and CE Mark approval to market its WallFlex Fully Covered Esophageal Stent in the U.S. and Europe. The new product is used for the treatment of malignant esophageal strictures (obstructions) caused by tumors in patients with resectable or non-resectable esophageal cancer.
With the new approval, Boston’s complete portfolio of WallFlex Stent family of self-expanding metal stents is now available in the U.S. , Europe and other international markets. The company had earlier receive< />< />< />< />< />< /><><><><><><><><>< /><>< /><>< /><>< /><>< /><>< /><>< /><><>< /><>< /><>< />< />...
|
FDA Nod for Gen-Probe Assay – Analyst Blog
|
|
|
Recently, Gen-Probe Inc. (GPRO) announced that it has received the green light from the U.S. Food and Drug Administration (FDA) to market ProParaflu Plus assay. The assay, developed by Prodesse, a wholly-owned subsidiary of Gen-Probe, is a molecular test for detecting and differentiating parainfluenza 1, 2, and 3 viruses that cause lower respiratory tract infections.
The assay makes use of real-time polymerase chain reaction to identify parainfluenza 1, 2, and 3 viruses from nasal swabs. Since it utilizes the same internal control as Prodesse's other tests for respiratory infectious diseas...
|
Abbott Deals for Drug Candidate – Analyst Blog
|
|
|
Abbott Labs (ABT) recently signed a definitive agreement with PanGenetics BV for a pain candidate, PG110. Under the terms of the agreement, Abbott will acquire global rights to PG110 which is a novel biologic that targets Nerve Growth Factor (NGF) for the treatment of chronic pain.
PanGenetics will receive an upfront payment of $170 million and $20 million in milestone payments. This agreement should allow Abbott to expand its pain product portfolio and leverage its expertise in biologics. The commercial opportunity in the pain market is significant. There is major demand for the development...
|
Becton Acquires HandyLab – Analyst Blog
|
|
|
Becton, Dickinson and Company (BDX) recently completed the acquisition of HandyLab, Inc, an Ann Arbor, Michigan-based company that develops and manufactures automation platforms and molecular diagnostic assays. The transaction costs Becton $275 million.
The acquisition enables Becton to develop and commercialize its BD GeneOhm molecular assays on the HandyLab Jaguar platform, the first fully integrated molecular diagnostic system. The HandyLab instrumentation technology is considered to be an industry leading molecular diagnostic automation platform.
With the acquisition, Becton plans to ...
|
Chasing Value: Ten stocks for 2010 -- Part 5
ABT
|
|
|
+2.20%
in
5 days
Filed under: Microsoft (MSFT), Abbott Laboratories (ABT), Chasing Value, Stocks to Buy  The march toward year end continues as three more stocks are reviewed in a search for the eventual 2010 stock picks. This year there will be nine stocks with a new wrinkle, I will add one naked put.
<>These options have contributed to a mind-boggling return on my 2009 portfolio, exceeding 200% to date. This has been a very unusual year, and I bet against the rampant fear in the market. I will not pretend for a moment that this is repeatable. What I will do is share my opinions and investing adventure, hoping ...
|
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
Visit streetinsider.com
Be the first to start a discussion and earn 2 points.
More Resources
|
About Abbott Laboratories
- Answers.com
